neoplasm metastasis/hypoxia

FIELD OF THE INVENTION The present disclosure relates generally to diagnostic techniques for cancer. More particularly, the present disclosure relates to biomarkers of cancer metastasis. BACKGROUND OF THE INVENTION Metastasis, the primary cause of cancer mortality is a complex process with multiple

FIELD OF THE INVENTION This application relates to the field of immune response, specifically to the use of bioactive agents (compounds) that interfere with HIF-1.alpha. expression and/or transcriptional activities and HIF-1.alpha. inhibitors and therefore modulate (i.e. decrease or increase)

INTRODUCTION The present invention relates a method for the treatment of cancer, especially esophagogastric cancer. The invention also relates to a pharmaceutical composition for the treatment of cancer. BACKGROUND TO THE INVENTION Cancers of the esophagogastric region are highly malignant tumours

INTRODUCTION The present invention relates a method for the treatment of cancer, especially esophagogastric cancer. The invention also relates to a pharmaceutical composition for the treatment of cancer. BACKGROUND TO THE INVENTION Cancers of the esophagogastric region are highly malignant tumours

TECHNICAL FIELD The present invention was made with the support of the Ministry of Education, Science, and Technology of Republic of Korea, under Project No. NRF-2012-003460, which was conducted under the research project entitled "General Researcher Support Project/Rising Researcher Support

CROSS-REFERENCES TO RELATED APPLICATION This patent application is a 371 of PCT/KR2011/007710, filed on Oct. 17, 2011, which claims the benefit of Korean Patent Application No. 10-2010-0102661, filed on Oct. 20, 2010, the contents of each of which are incorporated herein by reference. BACKGROUND OF